Skip to main content
    I

    INmune Bio Inc (INMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.10 (-9.87%)

    Market Cap: $32.51M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    INmune Bio Inc (INMB) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    INmune Bio (INMB) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, INmune Bio reported EPS of -$0.17, above the -$0.18 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    61%(19/31)
    Avg Surprise
    +1.09%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.20
    Range-$0.23 - -$0.15
    6 analysts
    Revenue Consensus
    N/A
    RangeN/A
    5 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.18
    Range-$0.18 - -$0.18
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.12-50.0%
    60d ago-$0.12-50.0%
    30d ago-$0.12-50.0%
    7d ago-$0.12-50.0%
    Current-$0.18
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Next Report

    INMB has an expected report date of Mar 29, 2027.

    INMB Earnings Call

    The latest INMB earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 31 quarters below that had an estimate, INMB beat 19 and missed 12. The widest gap in the table came in the quarter ended Sep 30, 2020, when EPS landed 111.76% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.17-$0.18-$0.20 - -$0.17+5.56%BeatN/A21 up, 0 downNov 5, 2026N/A
    Jun 30, 2026-$0.05-$0.20-$0.23 - -$0.17+75.00%BeatN/A21 up, 0 downAug 6, 2026N/A
    Mar 31, 2026-$0.20-$0.18-$0.19 - -$0.17-11.11%MissN/A21 up, 0 downMay 7, 2026N/A
    Dec 31, 2025-$0.18-$0.27-$0.31 - -$0.24+33.33%BeatN/A32 up, 0 downMar 30, 2026N/A
    Sep 30, 2025-$0.24-$0.32-$0.34 - -$0.31+25.00%BeatN/A21 up, 0 downOct 30, 2025N/A
    Jun 30, 2025-$0.34-$0.37-$0.41 - -$0.37+8.11%BeatN/A5N/AAug 7, 2025N/A
    Mar 31, 2025-$0.43-$0.45-$0.47 - -$0.43+4.44%BeatN/A43 up, 0 downMay 8, 2025$50000
    Dec 31, 2024-$0.40-$0.54-$0.58 - -$0.45+25.93%BeatN/A41 up, 2 downMar 27, 2025N/A
    Sep 30, 2024-$0.60-$0.49-$0.55 - -$0.42-22.45%MissN/A60 up, 0 downOct 31, 2024N/A
    Jun 30, 2024-$0.50-$0.62-$0.65 - -$0.62+19.35%BeatN/A30 up, 0 downAug 1, 2024N/A
    Mar 31, 2024-$0.61-$0.52-$0.55 - -$0.52-17.31%MissN/A21 up, 0 downMay 9, 2024$14000
    Dec 31, 2023-$0.47-$0.44-$0.53 - -$0.35-6.82%MissN/A20 up, 0 downMar 28, 2024$28000
    Sep 30, 2023-$0.48-$0.40-$0.42 - -$0.40-20.00%MissN/A20 up, 0 downNov 1, 2023$43000
    Jun 30, 2023-$0.36-$0.38-$0.42 - -$0.37+5.26%BeatN/A30 up, 0 downAug 7, 2023$46000
    Mar 31, 2023-$0.36-$0.02-$0.02 - -$0.02N/AN/AN/A10 up, 0 downMay 3, 2023$38000
    Dec 31, 2022-$0.32-$0.48-$0.50 - -$0.47+33.33%BeatN/A20 up, 0 downMar 2, 2023$97000
    Sep 30, 2022-$0.43-$0.52-$0.59 - -$0.46+17.31%BeatN/A20 up, 0 downNov 2, 2022$98000
    Jun 30, 2022-$0.38-$0.47N/A+19.15%BeatN/A20 up, 0 downAug 3, 2022$16000
    Mar 31, 2022-$0.39-$0.60-$0.60 - -$0.39+35.00%BeatN/A21 up, 0 downMay 5, 2022$163000
    Dec 31, 2021-$0.55-$0.58-$0.63 - -$0.54+5.17%BeatN/A3N/AMar 3, 2022$163000
    Sep 30, 2021-$0.55-$0.40-$0.43 - -$0.28-37.50%MissN/A30 up, 0 downNov 3, 2021$14000
    Jun 30, 2021-$0.44-$0.34-$0.36 - -$0.32-29.41%MissN/A4N/AAug 4, 2021N/A
    Mar 31, 2021-$0.32-$0.28-$0.32 - -$0.23-14.29%MissN/A3N/AMay 5, 2021$4000
    Dec 31, 2020-$0.26-$0.31-$0.38 - -$0.20+16.13%BeatN/A4N/AMar 4, 2021$11000
    Sep 30, 2020-$0.36-$0.17-$0.18 - -$0.16-111.76%MissN/A3N/ANov 5, 2020N/A
    Jun 30, 2020-$0.20-$0.23N/A+13.04%BeatN/A2N/AAug 5, 2020N/A
    Mar 31, 2020-$0.19-$0.21-$0.27 - -$0.14+9.52%BeatN/A3N/AMay 14, 2020N/A
    Dec 31, 2019-$0.22-$0.25-$0.29 - -$0.18+12.00%BeatN/A3N/AMar 11, 2020$77.69M
    Sep 30, 2019-$0.28-$0.19-$0.21 - -$0.18-47.37%MissN/A3N/ANov 8, 2019N/A
    Jun 30, 2019-$0.19-$0.20-$0.20 - -$0.18+5.00%BeatN/A2N/AAug 9, 2019N/A
    Mar 31, 2019-$0.20-$0.19-$0.19 - -$0.19-5.26%MissN/A1N/AMay 15, 2019N/A
    Dec 31, 2018-$0.21-$0.19N/A-10.53%MissN/AN/AN/AMar 29, 2019N/A
    Sep 30, 2018-$0.04N/AN/AN/AN/AN/AN/AN/ADec 21, 2018N/A
    Jun 30, 2018-$0.55N/AN/AN/AN/AN/AN/AN/AAug 30, 2018N/A
    Mar 31, 2018-$0.25N/AN/AN/AN/AN/AN/AN/AJun 13, 2018N/A
    Sep 30, 2017-$0.03N/AN/AN/AN/AN/AN/AN/ADec 1, 2017N/A
    Last 36 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.19, after -$2.11 the year before. It was -$1.08 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.19N/A
    Dec 31, 2024-$2.11N/A
    Dec 31, 2023-$1.67N/A
    Dec 31, 2022-$1.52N/A
    Dec 31, 2021-$1.86N/A
    Dec 31, 2020-$1.01N/A
    Dec 31, 2019-$0.89N/A
    Dec 31, 2018-$1.08N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,700 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,6796
    2026Q2Jun 30, 20263,7467
    2026Q1Mar 31, 20261,4735
    2025Q4Dec 31, 20253,6367
    2025Q3Sep 30, 20255,5929
    2025Q2Jun 30, 20255,46010
    2025Q1Mar 31, 20256,1249
    2024Q3Sep 30, 20245,17810

    2026Q3 Earnings Call

    Opening remarks

    Daniel Frederick Carlson Head of Investor Relations Thank you, operator, and good afternoon, everyone. We thank you for joining us for INmune Bio's third-quarter 2026 financial results call. Presenting on today's call are David J. Moss, CEO and co-founder of INmune Bio; Dr. Mark Lowdell, chief scientific officer and co-founder of INmune Bio; and Cory Ellspermann, INmune Bio's CFO. Before we begin, I remind everyone that, except for statements of historical fact, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those expressed or implied by such forward-looking statements. Please see the forward-looking statements disclaimer in the company's earnings press release, as well as the risk factors in the company's SEC filings, including our most recent quarterly filings with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. Now, it is my pleasure to turn the call over to INmune Bio's CEO, David J. Moss.

    David J. Moss CEO and Co-Founder Thank you, Daniel, and good afternoon, everyone. Thank you for joining us for INmune Bio's third-quarter 2026 earnings call. This is an exciting time for INmune Bio. We are getting close to important milestones and entering a new phase in the company's development as we move Ebstracel toward regulatory approval and prepare to make it available to patients. During the quarter, we made important progress in manufacturing, regulatory preparation, and international patient expansion. Each of these steps brings us closer to our goal of transforming INmune Bio from a clinical-stage company into a commercial-stage company. The immediate focus is on execution, as we are getting very close. This involves assembling the complete regulatory package, establishing a practical route to patient access, and carefully allocating capital to these milestones. I want to be clear about our confidence in these activities. We believe the clinical data presents a compelling case for Ebstracel as a potentially first-in-class systemic treatment for RDEB. Importantly, Ebstracel addresses the top concerns of RDEB patients: itch, pain, inflammation, and wounds. Combined with the progress we have made in manufacturing and our discussions with regulators, we believe we are in a strong position as we move toward approval. Of course, the final decision rests with the regulatory agencies, but our confidence in the program remains very high.

    Frequently Asked Questions About INMB

    When is INmune Bio's next earnings date?

    INmune Bio's next earnings report is expected for Mar 29, 2027.

    Did INMB beat earnings estimates last quarter?

    Yes. INmune Bio reported EPS of -$0.17 for the quarter ended Sep 30, 2026, above the -$0.18 estimate, a 5.56% surprise.

    What EPS do analysts expect from INMB next quarter?

    The consensus EPS estimate for INmune Bio for the quarter ending Dec 31, 2026 is -$0.20 from 6 analysts, with estimates from -$0.23 to -$0.15.

    How often does INMB beat earnings estimates?

    INmune Bio beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +20.78%.